Nanjing Bioheng Biotech completed a $15 million Series A financing, with all of the funds invested by Decheng Capital. Bioheng, which focuses on cell therapy products, is developing a universal CAR-T product that it expects will lower the cost of CAR-T therapies and solve the problem of graft v. host rejection. Founded in 2017, the company says it will use the proceeds to hire additional personnel, build GMP manufacturing facilities and develop its “off the shelf” universal immunotherapy products.
Source: China Biotoday
